07:00 , Jul 16, 2012 |  BC Week In Review  |  Company News

Orphan Synergy Europe-Pharma cancer news

Newco Orphan Synergy Europe-Pharma made its public debut with plans to revive development of a cancer vaccine developed more than a decade ago by co-founder Emile Loria at Epimmune Inc. OSE-Pharma acquired worldwide development rights...
00:05 , Jul 14, 2012 |  BC Extra  |  Company News

OSE-Pharma debuts to resume development of EP2101

Newco Orphan Synergy Europe-Pharma (Paris, France) made its public debut with plans to revive development of a cancer vaccine initially developed more than a decade ago by co-founder Emile Loria at San Diego-based Epimmune Inc....
07:00 , Apr 25, 2011 |  BC Week In Review  |  Company News

Biotech Synergy deal

Biotech Synergy acquired cancer candidate EP-2101 from an undisclosed company. The vaccine containing nine cytotoxic T lymphocyte epitopes from four tumor associated antigens (TAA) has completed a Phase II trial in non-small cell lung cancer...